A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)
Latest Information Update: 22 May 2023
At a glance
- Drugs EDP 305 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms ARGON-2
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 25 Apr 2023 Status changed from recruiting to discontinued.
- 07 Nov 2021 This trial has been discontinued in Germany (End date - 2021-10-05).
- 04 Oct 2021 Results presented in an Enanta Pharmaceuticals media release.